A Guide for Health Care Providers and Practice Administration

Montana

> Example EYLEA HD® (aflibercept) Injection Claim Issues and Applicable State Provisions

Prior Authorization	Prompt Payment	Request for Additional Information	Filing Deadlines	Provider Appeals
Issue: Plan delays prior authorization. Example scenario: Patient is diagnosed and meets medical necessity criteria for EYLEA HD injections. Provider submits a request for prior authorization. Plan has not made a decision. Montana Code Annotated Section 33-32-211 states For prospective review, the organization issues a determination within 7 business days of the receipt of request for a utilization management determination, if it is a nonurgent case; and for nonurgent cases, this period may be extended 1 time by the organization for up to 7 business days. 1) Provided that the organization determines that an extension is necessary because of matters beyond the control of the organization determines that an extension is necessary because of matters beyond the control of the organization and 2) Notifies the patient, prior to the expiration of the initial 15-calendar-day period, of the circumstances requiring the extension and the date when the Plan expects to make a decision, and 3) If a patient fails to submit the necessary information to decide the case, the notice of extension must specifically describe the required information, and the patient must be given at least 45 calendar days from receipt of notice to respond to the Plan request for more information. Montana Code Annotated Section 33-32-202 states Adverse determination also includes any prospective or retrospective review that denies, reduces, terminates, or fails to provide or to make payment in whole or in part for a benefit. Montana Code Annotated Section 33-32-221 states Section 1. Prior authorization requirements. (1) A Plan may not perform pior authorization on benefits for: (a) any generic prescription drug that is not listed within any of the schedules of controlled substances found at 21 CFR 1308.11 through 21 CFR 1308.15 or the schedules of controlled substances found in Title 50, chapter 32, after a covered person has already been subject to prior authorization on the grounds of therapeutic duplication for the same dosage of the pres	Issue: Plan delays timely payment pending medical necessity determination. Example scenario: Patient is diagnosed and meets medical necessity criteria for EYLEA HD injections. Provider submits a claim for EYLEA HD reimbursement, but 31 days later, claim is still pending medical necessity determination. Montana Code Annotated Section 33-18-232 states Plan will pay or deny a claim within 30 days of receiving proof of loss unless Plan makes a reasonable request for additional information or documents to evaluate the claim. If Plan fails to comply with these requirements and is liable for payment of the claim, Plan will pay an amount equal to the amount of the claim due plus 10% annual interest calculated from the date on which the claim was due.	Issue: Subsequent request for additional information. Example scenario: Provider submits a claim for EYLEA HD reimbursement, but 31 days later, Plan indicates payment of claim is pending receipt of additional information. Montana Code Annotated Section 33-18-232 states Plan will make a reasonable request for additional information or documents to evaluate the claim within 30 days of receiving proof of loss. If Plan has made a reasonable request for additional information or documents, Plan will pay or deny the claim within 60 days of receiving the proof of loss unless Plan has notified the insured person; assignee, or the claimant of the reasons for failure to pay the claim in full.	Issue: Claim is past the filing deadline. Example scenario: Provider timely submits an EYLEA HD claim. Plan denies the claim for being past the filing deadline. Group Health Insurance Standards Act Section 8 states Written proof of loss must be furnished to the insurer within 90 days after the date of loss. Failure to furnish the proof within that time will not invalidate nor reduce any claim if it was not reasonably possible to furnish proof within such time, provided the proof is furnished as soon as reasonably possible and in no event, except in the absence of legal capacity of the claimant, later than 1 year from the time proof is otherwise required. NOTE: This provision sets forth minimum standards. Provider should check contract for specific requirements. Montana Code Annotated Section 33-22-150 states If Plan limits the time in which a provider or other person is required to submit a claim for payment, Plan will have the same time limit following payment of the claim and requesting reimbursement for payment of an invalid claim or overpayment of a calaim.	Issue: Provider appeals. Example scenario: Provider wants to challenge Plan's denial or reduction of an EYLEA HD claim. Montana Code Annotated Section 33-32-308 states Internal appeal: After receiving a grievance request, Plan will issue a decision and send notification within a reasonable period of time that is appropriate, considering the covered person's medical condition, but no later than 30 days for a prospective review and no later than 60 days for a retrospective review. Montana Code Annotated Section 33-32-405 states Failure of Plan to respond within the appropriate time frame may allow the claimant to proceed to an external review. Montana Code Annotated Section 33-32-410 states An external review must be requested within 120 days and will be decided within 45 days. Montana Code Annotated Section 33-32-422 states Plan will pay for the costs of the external review.

Complaints regarding these and other payer issues can be made to the Office of the Montana State Auditor, Commissioner of Securities and Insurance website.



Visit NavigatingPayerChallenges.com for state-specific and federal legislation or contact your Reimbursement Business Manager (RBM) for more information



© 2025, Regeneron Pharmaceuticals, Inc. All rights reserved. 777 Old Saw Mill River Road, Tarrytown, NY 10591 05/2025 US.EHD.25.04.0018 This material is provided for informational purposes only, is subject to change, and should not be construed as legal or medical advice. Use of this information to challenge or appeal a coverage or reimbursement delay and/or denial by a payer is the responsibility of the provider.

(aflibercept) Injection 8 mg

This information is provided to you

by Regeneron the maker of

Reference: Data on file. Regeneron Pharmaceuticals, Inc.